Hepatocellular Carcinoma Market Analysis, Size, Share & Growth Forecast 2026–2034

Atezolizumab Plus Bevacizumab IMbrave150 42 Percent OS and 41 Percent PFS Hazard Reduction Versus Sorafenib Has Established the Anti-PD-L1 Plus Anti-VEGF Combination as the First-Line HCC Standard That Replaced the 2007 Sorafenib SHARP Trial Standard After 13 Years.Roche's IMbrave150 combination demonstrated 19.2 months median overall survival versus 13.4 months for sorafenib, and the 12-month overall survival of 67.2% versus 54.6% established a meaningful improvement in the proportion of patients surviving beyond one year in a disease where the prior standard had been the ceiling for over a decade. The immune-angiogenic combined effect hypothesis proposes that bevacizumab's VEGF blockade reduces immunosuppressive M2 macrophage polarisation and Treg accumulation in the tumour microenvironment that limits atezolizumab PD-L1 blockade efficacy when used alone, creating the mechanistic basis for combination superiority that was not predictable from single-agent trial data. Updated 3-year follow-up from IMbrave150 shows 24-month overall survival of 38.1% versus 29.1% for sorafenib, confirming durable benefit maintenance in the long-term survivor population that checkpoint-based therapy characteristically produces.

HIMALAYA STRIDE Tremelimumab Single-Priming Dose Plus Durvalumab 22 Percent Death Risk Reduction and 38.7 Versus 24.7 Percent 3-Year Survival Has Established the CTLA-4 Plus PD-L1 Dual Checkpoint Combination Achieving the Durable 3-Year HCC Survival Benefit.AstraZeneca's HIMALAYA demonstrated 16.4% reduction in death hazard for tremelimumab-durvalumab STRIDE regimen versus sorafenib, and the 36-month overall survival of 30.7% versus 24.0% establishes durable checkpoint combination benefit in a population where bevacizumab is contraindicated due to oesophageal varices, recent bleeding, or anti-VEGF intolerance. The single 300 mg priming dose of tremelimumab followed by durvalumab maintenance achieves CTLA-4 immune priming with lower cumulative CTLA-4 exposure than ipilimumab multiple-dose schedules, reducing the colitis and hepatitis adverse events that would be particularly consequential in a patient population with underlying chronic liver disease and impaired hepatic reserve. The HIMALAYA approval creates a clinical algorithm where hepatologists assess bevacizumab eligibility as the primary HCC first-line treatment decision, routing patients to atezolizumab-bevacizumab when bevacizumab is safe and to HIMALAYA when anti-VEGF use is contraindicated.

BCLC Staging System Integrating Tumour Stage, Child-Pugh Liver Function, ECOG Performance Status, and Portal Hypertension Guiding Resection for BCLC-0/A, TACE for BCLC-B, and Systemic Therapy for BCLC-C Has Established the HCC Treatment Allocation Framework That Liver Function Constraint Determines.Eisai's lenvatinib demonstrated non-inferior overall survival to sorafenib in REFLECT with a median of 13.6 versus 12.3 months and significantly higher objective response rate of 24.1% versus 9.2%, establishing lenvatinib as a more active single-agent TKI in HCC that achieves tumour size reduction in a larger proportion of patients. The AFP-100 ng/mL-below subgroup in REFLECT shows particularly favourable lenvatinib outcomes with median OS above 20 months, suggesting a biomarker-enriched population where lenvatinib monotherapy remains competitive with immunotherapy combination in the sorafenib-era benchmark patient population. LEAP-002 testing lenvatinib plus pembrolizumab versus lenvatinib plus placebo failed to demonstrate superiority of the combination in unselected HCC patients, limiting the immunotherapy-lenvatinib combination approach to the second-line and specific subgroup settings rather than broadly displacing first-line lenvatinib monotherapy with combination regimens.

For related market intelligence, see the Oncology Drug Market.